Controlled release of a model vaccine by nanoporous ceramic microneedle arrays

M.A. Boks, W.W.J. Unger, S. Engels, M. Ambrosini, Y. Van Kooyk, R. Luttge

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

15 Citaties (Scopus)

Uittreksel

Abstract Current vaccination technology can advance from the use of novel ceramic nanoporous microneedle arrays (npMNA), where the material serves as a storage reservoir for vaccines. Moreover, npMNA will enhance vaccine efficacy by more precisely reaching skin dendritic cells, the kickstarters of T and B cell immunity. In the present study we assessed the efficacy of vaccination using npMNAs by in vivo application of OVA257-264 peptides mixed with agonistic anti-CD40 antibodies as adjuvant. The induction of OVA-specific CD8+ T cells via npMNA was comparable with the frequency induced via intradermal injection using needle-syringe. However, only when expanding the vaccination area by using two npMNAs the frequencies of induced IFN-γ-specific effector CD8+ T cells were comparable with those induced via needle-syringe injection. Analysis of vaccine release from npMNA in a human ex vivo skin explant model revealed that OVA257-264 peptides were indeed delivered intradermal, and release also increased by prolonging the npMNA application time on the human skin. Together, our studies demonstrate the potential of npMNA for vaccine delivery in human skin and in vivo induction of CD8+ effector T cell responses.

TaalEngels
Artikelnummer14977
Pagina's375-383
Aantal pagina's9
TijdschriftInternational Journal of Pharmaceutics
Volume491
Nummer van het tijdschrift1-2
DOI's
StatusGepubliceerd - 14 jul 2015

Vingerafdruk

Ceramics
Vaccines
T-Lymphocytes
Vaccination
Syringes
Skin
Needles
Intradermal Injections
Peptides
Langerhans Cells
Anti-Idiotypic Antibodies
Immunity
B-Lymphocytes
Technology
Injections

Trefwoorden

    Citeer dit

    Boks, M. A., Unger, W. W. J., Engels, S., Ambrosini, M., Van Kooyk, Y., & Luttge, R. (2015). Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. International Journal of Pharmaceutics, 491(1-2), 375-383. [14977]. DOI: 10.1016/j.ijpharm.2015.06.025
    Boks, M.A. ; Unger, W.W.J. ; Engels, S. ; Ambrosini, M. ; Van Kooyk, Y. ; Luttge, R./ Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. In: International Journal of Pharmaceutics. 2015 ; Vol. 491, Nr. 1-2. blz. 375-383
    @article{73a6ba178ea2477883c9f1726115e5c3,
    title = "Controlled release of a model vaccine by nanoporous ceramic microneedle arrays",
    abstract = "Abstract Current vaccination technology can advance from the use of novel ceramic nanoporous microneedle arrays (npMNA), where the material serves as a storage reservoir for vaccines. Moreover, npMNA will enhance vaccine efficacy by more precisely reaching skin dendritic cells, the kickstarters of T and B cell immunity. In the present study we assessed the efficacy of vaccination using npMNAs by in vivo application of OVA257-264 peptides mixed with agonistic anti-CD40 antibodies as adjuvant. The induction of OVA-specific CD8+ T cells via npMNA was comparable with the frequency induced via intradermal injection using needle-syringe. However, only when expanding the vaccination area by using two npMNAs the frequencies of induced IFN-γ-specific effector CD8+ T cells were comparable with those induced via needle-syringe injection. Analysis of vaccine release from npMNA in a human ex vivo skin explant model revealed that OVA257-264 peptides were indeed delivered intradermal, and release also increased by prolonging the npMNA application time on the human skin. Together, our studies demonstrate the potential of npMNA for vaccine delivery in human skin and in vivo induction of CD8+ effector T cell responses.",
    keywords = "(Anti-tumor) CD8 T cell response, (Trans)dermal drug delivery, Ceramic nanoporous microneedles, Human skin, Vaccine delivery",
    author = "M.A. Boks and W.W.J. Unger and S. Engels and M. Ambrosini and {Van Kooyk}, Y. and R. Luttge",
    year = "2015",
    month = "7",
    day = "14",
    doi = "10.1016/j.ijpharm.2015.06.025",
    language = "English",
    volume = "491",
    pages = "375--383",
    journal = "International Journal of Pharmaceutics",
    issn = "0378-5173",
    publisher = "Elsevier",
    number = "1-2",

    }

    Boks, MA, Unger, WWJ, Engels, S, Ambrosini, M, Van Kooyk, Y & Luttge, R 2015, 'Controlled release of a model vaccine by nanoporous ceramic microneedle arrays' International Journal of Pharmaceutics, vol. 491, nr. 1-2, 14977, blz. 375-383. DOI: 10.1016/j.ijpharm.2015.06.025

    Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. / Boks, M.A.; Unger, W.W.J.; Engels, S.; Ambrosini, M.; Van Kooyk, Y.; Luttge, R.

    In: International Journal of Pharmaceutics, Vol. 491, Nr. 1-2, 14977, 14.07.2015, blz. 375-383.

    Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

    TY - JOUR

    T1 - Controlled release of a model vaccine by nanoporous ceramic microneedle arrays

    AU - Boks,M.A.

    AU - Unger,W.W.J.

    AU - Engels,S.

    AU - Ambrosini,M.

    AU - Van Kooyk,Y.

    AU - Luttge,R.

    PY - 2015/7/14

    Y1 - 2015/7/14

    N2 - Abstract Current vaccination technology can advance from the use of novel ceramic nanoporous microneedle arrays (npMNA), where the material serves as a storage reservoir for vaccines. Moreover, npMNA will enhance vaccine efficacy by more precisely reaching skin dendritic cells, the kickstarters of T and B cell immunity. In the present study we assessed the efficacy of vaccination using npMNAs by in vivo application of OVA257-264 peptides mixed with agonistic anti-CD40 antibodies as adjuvant. The induction of OVA-specific CD8+ T cells via npMNA was comparable with the frequency induced via intradermal injection using needle-syringe. However, only when expanding the vaccination area by using two npMNAs the frequencies of induced IFN-γ-specific effector CD8+ T cells were comparable with those induced via needle-syringe injection. Analysis of vaccine release from npMNA in a human ex vivo skin explant model revealed that OVA257-264 peptides were indeed delivered intradermal, and release also increased by prolonging the npMNA application time on the human skin. Together, our studies demonstrate the potential of npMNA for vaccine delivery in human skin and in vivo induction of CD8+ effector T cell responses.

    AB - Abstract Current vaccination technology can advance from the use of novel ceramic nanoporous microneedle arrays (npMNA), where the material serves as a storage reservoir for vaccines. Moreover, npMNA will enhance vaccine efficacy by more precisely reaching skin dendritic cells, the kickstarters of T and B cell immunity. In the present study we assessed the efficacy of vaccination using npMNAs by in vivo application of OVA257-264 peptides mixed with agonistic anti-CD40 antibodies as adjuvant. The induction of OVA-specific CD8+ T cells via npMNA was comparable with the frequency induced via intradermal injection using needle-syringe. However, only when expanding the vaccination area by using two npMNAs the frequencies of induced IFN-γ-specific effector CD8+ T cells were comparable with those induced via needle-syringe injection. Analysis of vaccine release from npMNA in a human ex vivo skin explant model revealed that OVA257-264 peptides were indeed delivered intradermal, and release also increased by prolonging the npMNA application time on the human skin. Together, our studies demonstrate the potential of npMNA for vaccine delivery in human skin and in vivo induction of CD8+ effector T cell responses.

    KW - (Anti-tumor) CD8 T cell response

    KW - (Trans)dermal drug delivery

    KW - Ceramic nanoporous microneedles

    KW - Human skin

    KW - Vaccine delivery

    UR - http://www.scopus.com/inward/record.url?scp=84937597799&partnerID=8YFLogxK

    U2 - 10.1016/j.ijpharm.2015.06.025

    DO - 10.1016/j.ijpharm.2015.06.025

    M3 - Article

    VL - 491

    SP - 375

    EP - 383

    JO - International Journal of Pharmaceutics

    T2 - International Journal of Pharmaceutics

    JF - International Journal of Pharmaceutics

    SN - 0378-5173

    IS - 1-2

    M1 - 14977

    ER -

    Boks MA, Unger WWJ, Engels S, Ambrosini M, Van Kooyk Y, Luttge R. Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. International Journal of Pharmaceutics. 2015 jul 14;491(1-2):375-383. 14977. Beschikbaar vanaf, DOI: 10.1016/j.ijpharm.2015.06.025